TOP > 外国特許検索 > GENETIC POLYMORPHISM USEFUL FOR PREDICTING TREATMENT EFFECTS OF CANCER IMMUNOTHERAPIES

GENETIC POLYMORPHISM USEFUL FOR PREDICTING TREATMENT EFFECTS OF CANCER IMMUNOTHERAPIES UPDATE

外国特許コード F160008651
整理番号 (S2014-0857-N0)
掲載日 2016年1月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP062595
国際公開番号 WO 2015163462
国際出願日 平成27年4月24日(2015.4.24)
国際公開日 平成27年10月29日(2015.10.29)
優先権データ
  • 特願2014-091677 (2014.4.25) JP
発明の名称 (英語) GENETIC POLYMORPHISM USEFUL FOR PREDICTING TREATMENT EFFECTS OF CANCER IMMUNOTHERAPIES UPDATE
発明の概要(英語) Provided is a composition, or a kit, for predicting the treatment effect of cancer immunotherapies, including a polynucleotide capable of detecting genetic polymorphism of an IL-6 receptor gene (IL-6R gene). Also provided is a method for predicting the treatment effects of cancer immunotherapies, that includes the detection of genetic polymorphism of the IL-6R gene.
従来技術、競合技術の概要(英語) BACKGROUND ART
1 Fourth leading cause of death of the malignant tumor can be at Japanese occupies about 33 million people die each year. In addition, each year about 600 million people in the world died in cancer. Current, cancer treatment methods include surgical resection, the anti-cancer agent, radiation therapy and the like are performed, none of these treatments is often decreases QOL. In addition, resistant to none of these treatments, other recurrence when the papermaking machine because there is no effective treatment, a cancer vaccine therapy as a therapy for cancer immunotherapy first are deficiencies of 4. However, cancer immunotherapy, there is no way to predict the effect of such treatment in advance, a patient can be expected to have a therapeutic effect selected in the situation there is no way. Heretofore, IL-6 receptor gene (hereinafter, also referred to as IL-6R gene) for the genetic polymorphism of genetic polymorphisms IL-6, (1) esophageal cancer patient (after surgery) correlates with the prognosis of, a genetic polymorphism of the receptor IL-6 IL-6R>C 48892A do not correlate with prognosis in patients with brain tumors ; (2) IL-6 correlates with prognosis of genetic polymorphisms of, IL-6 IL-6R>C 48892A receptor gene polymorphism may not correlate to the prognosis, and have been reported (non-patent document 1 and 2).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KURUME UNIVERSITY
  • NATIONAL UNIVERSITY CORPORATION AKITA UNIVERSITY
  • LSIP, LLC
  • 発明者(英語)
  • SASADA, Tetsuro
  • ITOH, Kyogo
  • MOTOYAMA, Satoru
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記問い合わせ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close